Source: EURLEX
Language: en
Format: md

|  |  |  |  |
| --- | --- | --- | --- |
| 12.11.2018 | EN | Official Journal of the European Union | C 408/48 |

---

Judgment of the General Court of 25 September 2018 — Amicus Therapeutics UK and Amicus Therapeutics v EMA

(Case T-33/17) [(1)](#ntr1-C_2018408EN.01004801-E0001)

((Access to documents - Regulation (EC) No 1049/2001 - Documents held by the EMA and submitted as part of the request for authorisation to place the medicinal product Galafold on the market - Decision to grant a third party access to a document - Exception relating to the protection of commercial interests - No general presumption of confidentiality))

(2018/C 408/60)

Language of the case: English

Parties

Applicants: Amicus Therapeutics UK Ltd (Gerrards Cross, United Kingdom) and Amicus Therapeutics, Inc. (Cranbury, New Jersey, United States) (represented by: L. Tsang, J. Mulryne, Solicitors, and F. Campbell, Barrister)

Defendant: European Medicines Agency (EMA) (represented by N. Rampal Olmedo, S. Marino, A. Spina, A. Rusanov and T. Jabłoński, acting as Agents)

Re:

Action under Article 263 TFEU for the annulment of EMA Decision ASK-22072 of 14 December 2016, granting to a third party, pursuant to Regulation (EC) No 1049/2001 of the European Parliament and of the Council of 30 May 2001 regarding public access to European Parliament, Council and Commission documents ([OJ 2001 L 145, p. 43](./../../../legal-content/EN/AUTO/?uri=OJ:L:2001:145:TOC)), access to a document containing information submitted in the context of a request for marketing authorisation for the medicinal product Galafold.

Operative part of the judgment

The Court:

|  |  |
| --- | --- |
| 1. | Dismisses the action; |

|  |  |
| --- | --- |
| 2. | Orders Amicus Therapeutics UK Ltd and Amicus Therapeutics, Inc. to pay the costs. |

---

---

[Top](#document1)